| abstract |
Refers to a conjugate comprising a glucagon 1-like peptide fusion peptide (GLP-1) coupled to a cyclic tyrosine tyrosine (PYY) peptide, wherein the GLP-1 fusion peptide comprises a GLP-1 peptide, a first peptide linker, a hinge-Fc region peptide, and a second linker peptide, wherein the first linker peptide is optionally absent; wherein the cyclic PYY peptide is represented by formula I, or a derivative or pharmaceutically acceptable salt thereof. Where: p is 0 or 1; m is 0, 1, 2, 3, 4, or 5; n is 1, 2, 3, or 4; q is 0 or 1; provided that q is 1 only when Z30 is absent; BRIDGE is -Ph-CH2-S-, -triazolyl-, -NHC (O) CH2S-, -SCH2C (O) NH-; Z4 is K, A, E, S, or R; Z7 is A or K; Z9 is G or K; Z11 is D or K; Z22 is A or K; Z23 is S or K; Z26 is A or H; Z30 is L, W, or is absent. Wherein the GLP-1 peptide comprises an amino acid sequence selected from the group consisting of SEQ ID No: 56-59; the first linker peptide is present and comprises an amino acid sequence selected from the group consisting of SEQ ID No: 60-83; the hinge region-Fc peptide comprises an amino acid sequence selected from the group consisting of SEQ ID No: 84-90; the second linker peptide comprises an amino acid sequence selected from the group consisting of SEQ ID No: 93-112. It also refers to a method of producing said conjugate, a pharmaceutical composition, wherein the pharmaceutical composition is administered by injection. A method for treating or preventing a disease or disorder in a subject in need thereof, wherein said disease or disorder is obesity, type I or type II diabetes, metabolic syndrome, among others. |